Why pharma manufacturers are still investing in Europe
Undeterred by tariffs and global competition, pharma manufacturers are seeing an opportunity in Europe and continuing to invest accordingly. Europe’s share …
Post
-
-
Novo Nordisk shares tumble 18% after 2026 sales dip warning
Shares in Novo Nordisk have plummeted after the drugmaker forecast a dip in sales and profit growth below analyst expectations …
-
Relay Therapeutics’ zovegalisib secures FDA BTD for advanced breast cancer
Relay Therapeutics has received the US Food and Drug Administration (FDA) breakthrough therapy designation (BTD) for zovegalisib (RLY-2608), along with …
-
CEPI and Samsung Biologics partner to boost global vaccine preparedness
The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics have partnered in an outbreak-ready vaccine manufacturing partnership to enhance …
-
Pfizer sets sights on R&D strategy amid modest FY25 results
New York-based pharma giant Pfizer has met targets for its fiscal year 2025 (FY25) financials, which come as the company …
-
MSD’s 2026 sales forecast falls short amid patent losses despite strong Q4
Despite posting strong results in the final quarter of 2025, MSD (Merck & Co) has cut its 2026 guidance more …
-
Podcast: driving linked data insights, the complexities, and experiences
This is the final episode in season one of Insights Uncovered: A Real-World Data Podcast Series from GlobalData, presented by …
-
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
SanegeneBio has entered a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its ribonucleic …
-
Aquestive receives FDA CRL for Anaphylm allergic reaction treatment
Aquestive Therapeutics has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new …
-
Eli Lilly selects Pennsylvania for $3.5bn manufacturing site of obesity drugs
Eli Lilly has chosen Pennsylvania to house a new $3.5bn manufacturing facility that will produce a forthcoming wave of new …
-
Amgen hands back eczema drug to Kyowa Kirin despite positive late-stage data
Amgen is handing back the rights of its successful in-licensed atopic dermatitis (AD) asset, rocatinlimab, to Kyowa Kirin. In a statement …
-
CHMP grants positive opinion for J&J’s Akeega use
Johnson & Johnson (J&J) has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for …
-
CIRM unveils RAPID funding programme for rare diseases
The California Institute for Regenerative Medicine (CIRM) in the US has approved the Rare Disease Acceleration Platform and Innovation and …
-
FDA’s new scheme to boost US manufacturing commences despite uncertainty
The US Food and Drug Administration (FDA) will start accepting applications for the new PreCheck scheme that will streamline the …
-
Sanofi touts strong new launch sales amid looming Dupixent patent expiry
Sanofi is making successful strides to restock its pipeline and shore up revenue streams amid the looming patent expiry of …
